| Pharmaceutical Information |
| Drug Name |
Amprenavir |
| Drug ID |
BADD_D00136 |
| Description |
Amprenavir is a protease inhibitor used to treat HIV infection. |
| Indications and Usage |
For the treatment of HIV-1 infection in combination with other antiretroviral agents. |
| Marketing Status |
Discontinued |
| ATC Code |
J05AE05 |
| DrugBank ID |
DB00701
|
| KEGG ID |
D00894
|
| MeSH ID |
C095108
|
| PubChem ID |
65016
|
| TTD Drug ID |
D0A0OO
|
| NDC Product Code |
Not Available |
| Synonyms |
amprenavir | tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate | (3S-(3R*(1R*,2S*)))-(3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate | VX 478 | VX-478 | Vertex VX478 | Agenerase |
|
| Chemical Information |
| Molecular Formula |
C25H35N3O6S |
| CAS Registry Number |
161814-49-9 |
| SMILES |
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
|
|
| ADRs Induced by Drug |
|
|
